Zobrazeno 1 - 10
of 53
pro vyhledávání: '"J. David Lawson"'
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 8, p 7373 (2023)
Within the MAPK/RAS pathway, there exists a plethora of protein–protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much needed therapies for patients with KRAS-mutant
Externí odkaz:
https://doaj.org/article/d6ea944e51574cda868cf8e0b01374aa
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Autor:
John M. Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns, Robin J. Gunn, Anthony Ivetac, Jon Kuehler, Svitlana Kulyk, Jade Laguer, J. David Lawson, Krystal Moya, Natalie Nguyen, Lisa Rahbaek, Barbara Saechao, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Laura Vegar, Darin Vanderpool, Xiaolun Wang, Larry Yan, Peter Olson, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:9678-9690
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS
Autor:
Patrick Vincent, Barbara Hibner, Ron de Jong, Hidehisa Iwata, Akio Mizutani, Akira Hori, Kengo Okada, J. David Lawson, Shaosong Chu, Ruhi Kamran, Mark S. Hixon, Shweta Pandya, Deepika Balakrishna, Jennifer Matuszkiewicz, Pamela J. Farrell
Supplemental Table 1. Activity of MET TKIs in enzyme and cellular assessments Supplemental Table 2. Activity of Compound 1 against approximately 130 additional protein kinases. Figure S1. Binding modes of selective MET TKIs. Figure S2. MET TKI, Compo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120f016d9ddd8b8907dbb9ab603d8673
https://doi.org/10.1158/1535-7163.22504134
https://doi.org/10.1158/1535-7163.22504134
Autor:
Patrick Vincent, Barbara Hibner, Ron de Jong, Hidehisa Iwata, Akio Mizutani, Akira Hori, Kengo Okada, J. David Lawson, Shaosong Chu, Ruhi Kamran, Mark S. Hixon, Shweta Pandya, Deepika Balakrishna, Jennifer Matuszkiewicz, Pamela J. Farrell
Receptor tyrosine kinase therapies have proven to be efficacious in specific cancer patient populations; however, a significant limitation of tyrosine kinase inhibitor (TKI) treatment is the emergence of resistance mechanisms leading to a transient,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a781388f16b2563b61d0736ccfdad587
https://doi.org/10.1158/1535-7163.c.6537630
https://doi.org/10.1158/1535-7163.c.6537630
Autor:
Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M. Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J. David Lawson, Krystal Moya, Peter Olson, Lisa Rahbaek, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:1749-1766
Autor:
Christopher R. Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, Valentina Arkhipova, James G. Christensen, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Nicole C. Thomas, Xiaolun Wang, Matthew A. Marx
Publikováno v:
RSC Medicinal Chemistry. 13:1549-1564
Herein we describe our approach to prioritize five fragment hits with the objective of answering three questions: could the binding potency be improved? Were the series chemically tractable? Could additional co-crystal structures be solved?
Autor:
Xiaolun Wang, Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan, Joshua R. Dahlke, Jay B. Fell, John P. Fischer, Robin J. Gunn, Jill Hallin, Jade Laguer, J. David Lawson, James Medwid, Brad Newhouse, Phong Nguyen, Jacob M. O’Leary, Peter Olson, Spencer Pajk, Lisa Rahbaek, Mareli Rodriguez, Christopher R. Smith, Tony P. Tang, Nicole C. Thomas, Darin Vanderpool, Guy P. Vigers, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:3123-3133
Autor:
Mark Sabat, Douglas R Dougan, Beverly Knight, J. David Lawson, Nicholas Scorah, Christopher R Smith, Ewan R Taylor, Phong Vu, Corey Wyrick, Haixia Wang, Deepika Balakrishna, Mark Hixon, Loui Madakamutil, Donavon McConn
Publikováno v:
Journal of Medicinal Chemistry. 64:12893-12902
Autor:
Christopher R. Smith, Ruth Aranda, James G. Christensen, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Matthew A. Marx, Peter Olson, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Svitlana Kulyk
Publikováno v:
Bioorganicmedicinal chemistry. 71
MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral synthesis or a chiral separation step in its prepara